TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

TransMedics Group (TMDX) will release its third-quarter 2026 financial results after market close on November 5, 2026.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

TransMedics Group (TMDX) will release its third-quarter 2026 financial results after market close on November 5, 2026. Management will host a corresponding conference call at 4:30 p.m. ET / 1:30 p.m. PT. A live and archived webcast will be available in the Investors section of the company website.

Key Figures

Results release date: November 5, 2026

Results release date: November 5, 2026; Third-quarter 2026 financial results scheduled after market close

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/22/2026 - 04:05 PM EDT

ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 6054544. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Gilmartin Group
Investors@transmedics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2026-financial-results-on-november-5-2026-302917373.html